BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33793313)

  • 1. Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.
    Schmidt AL; Tabakin AL; Singer EA; Choueiri TK; McKay RR
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-11. PubMed ID: 33793313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing Therapies for Metastatic Renal Cell Carcinoma.
    Dizman N; Arslan ZE; Feng M; Pal SK
    Urol Clin North Am; 2020 Aug; 47(3):305-318. PubMed ID: 32600533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
    Atkins MB; Tannir NM
    Cancer Treat Rev; 2018 Nov; 70():127-137. PubMed ID: 30173085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary treatment of metastatic renal cell carcinoma.
    Wiechno P; Kucharz J; Sadowska M; Michalski W; Sikora-Kupis B; Jonska-Gmyrek J; Poniatowska G; Nietupski K; Ossolinski K; Demkow T
    Med Oncol; 2018 Oct; 35(12):156. PubMed ID: 30368624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy of metastatic renal cell carcinoma: Review of the current literature.
    Zerdes I; Tolia M; Tsoukalas N; Mitsis M; Kardamakis D; Pistevou-Gombaki K; Tsekeris P; Kyrgias G
    Urologia; 2019 Feb; 86(1):3-8. PubMed ID: 30270773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapeutic approaches in renal cell carcinoma.
    Parekh H; Rini BI
    Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
    Considine B; Hurwitz ME
    Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney Cancer: An Overview of Current Therapeutic Approaches.
    Chowdhury N; Drake CG
    Urol Clin North Am; 2020 Nov; 47(4):419-431. PubMed ID: 33008493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma.
    Chang AJ; Zhao L; Zhu Z; Boulanger K; Xiao H; Wakefield MR; Bai Q; Fang Y
    Anticancer Res; 2019 Jun; 39(6):2683-2687. PubMed ID: 31177102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
    Massari F; Nunno VD; Mollica V; Montironi R; Cheng L; Cimadamore A; Blanca A; Lopez-Beltran A
    Immunotherapy; 2019 Dec; 11(17):1507-1521. PubMed ID: 31663411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.